NCT06283316 Systemic Treatments for Alopecia Areata Registry
| NCT ID | NCT06283316 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Erasmus Medical Center |
| Condition | Alopecia Areata |
| Study Type | OBSERVATIONAL |
| Enrollment | 10,000 participants |
| Start Date | 2024-01-17 |
| Primary Completion | 2099-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10,000 participants in total. It began in 2024-01-17 with a primary completion date of 2099-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A multicenter prospective registry (STA2R) is conducted to assess systemic treatments for alopecia areata, focusing on effectiveness, safety, and long-term outcomes.
Eligibility Criteria
Inclusion Criteria: * Diagnosed with alopecia areata; * Starting/using a systemic treatment for alopecia areata; * Informed consent for registry participation obtained from patient and/or caretaker. Exclusion Criteria: * Not sufficiently capable of understanding the Dutch language; * Not willing to participate.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06283316 clinical trial?
This trial is open to participants of all sexes, aged 16 Years or older, studying Alopecia Areata. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06283316 currently recruiting?
Yes, NCT06283316 is actively recruiting participants. Contact the research team at d.hijnen@erasmusmc.nl for enrollment information.
Where is the NCT06283316 trial being conducted?
This trial is being conducted at Rotterdam, Netherlands.
Who is sponsoring the NCT06283316 clinical trial?
NCT06283316 is sponsored by Erasmus Medical Center. The trial plans to enroll 10,000 participants.